The cash capital increase of Ledgertech SE (in future SynBiotic SE) by 1.25 million new shares to 1.5 million shares at an issue price of EUR 1 per share, as approved by the Annual General Meeting on April 8, 2020, was placed in full with investors. The capital increase was accompanied by Small & Mid Cap Investmentbank AG, Munich.
This clears the way for the implementation of the company’s realignment: With a focused buy-and-build strategy, we want to build a diversified group of companies that focuses on the use of cannabis products in medicine, cosmetics and nutrition. The range of products will include the alternative production of functionally superior cannabinoids and other psychoactive molecules as well as the development of prescription drugs and the production and distribution of over-the-counter wellness products (food supplements and cosmetics) for end customers under our own brands.
In order to reflect the new strategy in the name as well, the Annual General Meeting had decided to rename the company SynBiotic SE. As soon as the name change is entered in the commercial register, the shares will also be converted in the various databases such as comdirect, Onvista and Bloomberg. Until then, the shares will still trade under “Ledgertech” (ISIN: DE000A2LQ777)
Ledgertech/SynBiotic is in discussions with several potential acquisition candidates and is confident to announce first acquisitions in the near future.
The online address is now: www.synbiotic.com